Novavax (NVAX) - Get Report and Johnson & Johnson (JNJ) - Get Report have a new Covid-19 customer: the U.K.,which has agreed to buy as many as 90 million doses of their yet-to-be-proven-effective coronavirus vaccines that are still in early-trial stages.
The U.K. government ordered 60 million doses of Novavax’s late-stage experimental vaccine, which may be available as early as the first quarter of 2021, the U.S. biotechnology company said in a statement Friday.
J&J’s Janssen unit said in a separate statement that it has received an order for 30 million doses of its own Covid-19 trial vaccine.
The agreements come as countries around the world continue to race to secure a viable Covid-19 vaccine - even though one has yet to be created and approved.
The agreements with Novavax and J&J bring the total number of potential vaccine doses secured by the U.K. to more than 300 million. The country of 66 million has also signed deals with partners GlaxoSmithKline (GSK) - Get Report and Sanofi (SNY) - Get Report, Pfizer (PFE) - Get Report and BioNTech (BNTX) - Get Report.
The University of Oxford and AstraZeneca (AZN) - Get Report are also prepping to make as many as 30 million doses of their own Covid-19 vaccine candidate available within the U.K. by September as part of a deal to deliver 100 million doses.
Latest Videos From TheStreet and Jim Cramer:
- Apple Looks to Take on Amazon With 'Apple One'
- Coronavirus Update: Novovax, J&J Pen Deals With U.K. for Vaccine Delivery
- Airbnb Must Be Doing Better Than I Thought, Jim Cramer Says
- What Is a Reopening Stock?
- Jim Cramer: Football Is Uniquely Bad for COVID-19
- Microsoft Debuts Foldable Phone: Everything We Know So Far
- Jim Cramer on Tesla: Stocks Shouldn't Be Up After Stock Splits